Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Generation Change 4.0 at Ottobock

Otto Bock HealthCare GmbH
Posted on: 15 Sep 17
Generation Change 4.0 at Ottobock

PR Newswire

DUDERSTADT, Germany, September 15, 2017

DUDERSTADT, Germany, September 15, 2017 /PRNewswire/ --

German medtech company sets course for future

Prof. Hans Georg Näder's youngest daughter, Georgia, will in future be representing the family on Ottobock's supervisory board, which is currently being formed. Otto Bock HealthCare GmbH, based in the German state of Lower Saxony, is undergoing the conversion to an SE & Co. KGaA. Georgia Näder will therefore also be enlisted to the executive board of Otto Bock Holding GmbH & Co. KG.

     (Photo: http://mma.prnewswire.com/media/556755/Georgia_Nader.jpg )
     (Photo: http://mma.prnewswire.com/media/556754/Dr__Oliver_Scheel.jpg )

Following nearly three decades in his role as CEO at Otto Bock HealthCare GmbH, Prof. Hans Georg Näder (56) will be assuming the leadership of the supervisory board of the future Ottobock SE & Co. KGaA as chairman of the board. Dr Oliver Scheel (49) will take over the role of CEO on 15 January 2018.

The appointment of Dr Scheel, a long-time partner and managing director at consulting company A.T. Kearney and head of their pharma, medical technology and healthcare department who possesses extensive expertise in the subject of transformation management, represents the first time in Ottobock's history that a manager from outside the family has taken the helm of the German-based "hidden champion" and global market leader in the field of technical orthopaedics.

Longstanding CFO Harry Wertz (60) will exclusively continue his role as CEO with the Otto Bock Holding GmbH & CoKG.

The head of the Näder Family Office, Stefan Hirsch (45), was also enlisted to the executive board of Otto Bock Holding GmbH & Co. KG as part of the developments within the company.

Further information: http://www.ottobock.com/en/press/press-releases/news-overview-page-2.0.html

Head of Investor Relations / Corporate Communications
Mark C. Schneider
Phone: +49(0)30-398-206-222 / mobile: +49(0)151-146-591-35
Email: MarkC.Schneider@ottobock.de


SOURCE Otto Bock HealthCare GmbH

PR Newswire
www.prnewswire.com

Last updated on: 15/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.